Advertisement
CNTX vs MREO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNTX is a Hold and MREO is a Hold.
CNTX's Indicator enters downward trend
The Aroon Indicator for CNTX entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 278 similar instances where the Aroon Indicator formed such a pattern. In 262 of the 278 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CNTX's RSI Indicator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for CNTX just turned positive on November 04, 2026. Looking at past instances where CNTX's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +1.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNTX advanced for three days, in 211 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
CNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.466) is normal, around the industry mean (3.498). P/E Ratio (-0.403) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MREO sees its Stochastic Oscillator climbs out of oversold territory
On October 29, 2026, the Stochastic Oscillator for MREO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In 57 of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MREO as a result. In 84 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
Following a +5.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MREO turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MREO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MREO crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MREO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (3.498). P/E Ratio (-1.415) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (102.041) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MREO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | |
P/E GROWTH RATING 1..100 | 36 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CNTX | MREO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 88% | N/A |
| Stochastic ODDS (%) | N/A | 4 days ago 90% |
| Momentum ODDS (%) | N/A | 4 days ago 88% |
| MACD ODDS (%) | 4 days ago 88% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 88% | 4 days ago 87% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| Advances ODDS (%) | 15 days ago 89% | 6 days ago 81% |
| Declines ODDS (%) | 11 days ago 89% | 15 days ago 86% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 88% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CNTX’s FA Score shows that 1 FA rating(s) are green while MREO’s FA Score has 0 green FA rating(s).
- CNTX’s FA Score: 1 green, 4 red.
- MREO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CNTX’s TA Score shows that 4 TA indicator(s) are bullish while MREO’s TA Score has 4 bullish TA indicator(s).
- CNTX’s TA Score: 4 bullish, 2 bearish.
- MREO’s TA Score: 4 bullish, 5 bearish.
Price Growth
CNTX (@Biotechnology) experienced а +2.33% price change this week, while MREO (@Biotechnology) price change was -2.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
CNTX is expected to report earnings on Mar 24, 2027.
MREO is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNTX has been loosely correlated with ELTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CNTX jumps, then ELTX could also see price increases.
| Ticker / NAME | Correlation To CNTX | 1D Price Change % | ||
|---|---|---|---|---|
| CNTX | 100% | +2.98% | ||
| ELTX - CNTX | 42% Loosely correlated | +7.86% | ||
| NMRA - CNTX | 39% Loosely correlated | +3.35% | ||
| PROK - CNTX | 29% Poorly correlated | +7.04% | ||
| TRAW - CNTX | 27% Poorly correlated | +0.77% | ||
| MREO - CNTX | 27% Poorly correlated | +0.93% | ||
More | ||||
MREO and
Correlation & Price change
A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.
| Ticker / NAME | Correlation To MREO | 1D Price Change % | ||
|---|---|---|---|---|
| MREO | 100% | +0.93% | ||
| RARE - MREO | 58% Loosely correlated | -0.90% | ||
| TRDA - MREO | 40% Loosely correlated | +7.47% | ||
| SYRE - MREO | 38% Loosely correlated | +7.53% | ||
| XNCR - MREO | 38% Loosely correlated | +4.99% | ||
| NRIX - MREO | 38% Loosely correlated | +3.10% | ||
More | ||||